Premium
Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ ‐1945 in a mouse traumatic brain injury model
Author(s) -
Bains Mona,
Cebak John E.,
Gilmer Lesley K.,
Barnes Colleen C.,
Thompson Stephanie N.,
Geddes James W.,
Hall Edward D.
Publication year - 2013
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.12118
Subject(s) - spectrin , calpain , traumatic brain injury , pharmacology , neurodegeneration , cytoskeleton , medicine , chemistry , cell , biochemistry , disease , psychiatry , enzyme
Abstract The efficacy of the amphipathic ketoamide calpain inhibitor SNJ ‐1945 in attenuating calpain‐mediated degradation of the neuronal cytoskeletal protein α‐spectrin was examined in the controlled cortical impact ( CCI ) traumatic brain injury ( TBI ) model in male CF ‐1 mice. Using a single early (15 min after CCI ‐ TBI ) i.p. bolus administration of SNJ ‐1945 (6.25, 12.5, 25, or 50‐mg/kg), we identified the most effective dose on α‐spectrin degradation in the cortical tissue of mice at its 24 h peak after severe CCI ‐ TBI . We then investigated the effects of a pharmacokinetically optimized regimen by examining multiple treatment paradigms that varied in dose and duration of treatment. Finally, using the most effective treatment regimen, the therapeutic window of α‐spectrin degradation attenuation was assessed by delaying treatment from 15 min to 1 or 3 h post‐injury. The effect of SNJ ‐1945 on α‐spectrin degradation exhibited a U‐shaped dose–response curve when treatment was initiated 15 min post‐ TBI . The most effective 12.5 mg/kg dose of SNJ ‐1945 significantly reduced α‐spectrin degradation by ~60% in cortical tissue. Repeated dosing of SNJ ‐1945 beginning with a 12.5 mg/kg dose did not achieve a more robust effect compared with a single bolus treatment, and the required treatment initiation was less than 1 h. Although calpain has been firmly established to play a major role in post‐traumatic secondary neurodegeneration, these data suggest that even brain and cell‐permeable calpain inhibitors, when administered alone, do not show sufficient cytoskeletal protective efficacy or a practical therapeutic window in a mouse model of severe TBI . Such conclusions need to be verified in the human clinical situation.